Cellosaurus HT115 (CVCL_2520)

Cell line name HT115
Synonyms HT-115; HT 115
Accession CVCL_2520
Resource Identification Initiative To cite this cell line use: HT115 (RRID:CVCL_2520)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Microsatellite instability: Stable (MSS) (PubMed=25926053); Instable (MSI-low) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Colon carcinoma (NCIt: C4910)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; ECACC; PubMed=25877200

Markers:
AmelogeninX
CSF1PO7,12
D13S31713
D16S53910
D18S5112,15
D21S1130,32.2
D3S135817
D5S81812
D7S82011,12
D8S117913,15
FGA19,20
Penta D12
Penta E11,12
TH016,9
TPOX8
vWA18
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=HT115
http://tcpaportal.org/mclp/
Publications

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002-7002(2015)

DOI=10.1101/092767
Roumeliotis T.I., Williams S.P., Goncalves E., Zamanzad G.F., Aben N., Michaut M., Schubert M., Wright J.C., Yang M., Alsinet C., Dienstmann R., Guinney J., Beltrao P., Brazma A., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Genomic determinants of protein abundance variation in colorectal cancer cells.
bioRxiv 2016:092767-092767(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ECACC; 85061104
Cell line databases/resources CLDB; cl1756
CCLE; HT115_LARGE_INTESTINE
ColonAtlas; HT115
Cosmic-CLP; 907289
GDSC; 907289
LINCS_LDP; LCL-1162
Ontologies BTO; BTO:0003460
CLO; CLO_0004277
EFO; EFO_0006442
Biological sample resources BioSample; SAMN03472979
Gene expression databases GEO; GSM827330
GEO; GSM887137
GEO; GSM888208
GEO; GSM1346843
GEO; GSM1448111
GEO; GSM1669909
Polymorphism and mutation databases Cosmic; 1609486
Cosmic; 2301987